SMT201700539T1 - DERIVATI IMIDAZO[1,2-b]PIRIDAZINICI COME INIBITORI DI CHINASI - Google Patents

DERIVATI IMIDAZO[1,2-b]PIRIDAZINICI COME INIBITORI DI CHINASI

Info

Publication number
SMT201700539T1
SMT201700539T1 SM20170539T SMT201700539T SMT201700539T1 SM T201700539 T1 SMT201700539 T1 SM T201700539T1 SM 20170539 T SM20170539 T SM 20170539T SM T201700539 T SMT201700539 T SM T201700539T SM T201700539 T1 SMT201700539 T1 SM T201700539T1
Authority
SM
San Marino
Prior art keywords
imidazo
kinase inhibitors
pyridazine derivatives
pyridazine
derivatives
Prior art date
Application number
SM20170539T
Other languages
English (en)
Italian (it)
Inventor
Yuichi Tominaga
Yasuyuki Takeda
Kenji Yoshikawa
Yoshiko Kagoshima
Yuko Yamamoto
Ryoichi Tanaka
Masaki Kiga
Yoshito Hamada
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SMT201700539T1 publication Critical patent/SMT201700539T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20170539T 2012-06-04 2013-06-03 DERIVATI IMIDAZO[1,2-b]PIRIDAZINICI COME INIBITORI DI CHINASI SMT201700539T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012127079 2012-06-04
EP13801320.6A EP2857404B1 (en) 2012-06-04 2013-06-03 IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
PCT/JP2013/065328 WO2013183578A1 (ja) 2012-06-04 2013-06-03 キナーゼ阻害剤としてのイミダゾ[1,2-b]ピリダジン誘導体

Publications (1)

Publication Number Publication Date
SMT201700539T1 true SMT201700539T1 (it) 2018-01-11

Family

ID=49711970

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20170539T SMT201700539T1 (it) 2012-06-04 2013-06-03 DERIVATI IMIDAZO[1,2-b]PIRIDAZINICI COME INIBITORI DI CHINASI

Country Status (32)

Country Link
US (2) US9187489B2 (cg-RX-API-DMAC7.html)
EP (1) EP2857404B1 (cg-RX-API-DMAC7.html)
JP (1) JP5814467B2 (cg-RX-API-DMAC7.html)
KR (1) KR101781255B1 (cg-RX-API-DMAC7.html)
CN (1) CN104520300B (cg-RX-API-DMAC7.html)
AU (1) AU2013272701B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029851B1 (cg-RX-API-DMAC7.html)
CA (1) CA2874819C (cg-RX-API-DMAC7.html)
CO (1) CO7160119A2 (cg-RX-API-DMAC7.html)
CY (1) CY1119607T1 (cg-RX-API-DMAC7.html)
DK (1) DK2857404T3 (cg-RX-API-DMAC7.html)
ES (1) ES2648228T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171724T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037221T2 (cg-RX-API-DMAC7.html)
IL (1) IL236075A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN02497A (cg-RX-API-DMAC7.html)
LT (1) LT2857404T (cg-RX-API-DMAC7.html)
MX (1) MX357021B (cg-RX-API-DMAC7.html)
MY (1) MY170326A (cg-RX-API-DMAC7.html)
NO (1) NO2857404T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ702574A (cg-RX-API-DMAC7.html)
PH (1) PH12014502721A1 (cg-RX-API-DMAC7.html)
PL (1) PL2857404T3 (cg-RX-API-DMAC7.html)
PT (1) PT2857404T (cg-RX-API-DMAC7.html)
RS (1) RS56625B1 (cg-RX-API-DMAC7.html)
RU (1) RU2635917C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201408052WA (cg-RX-API-DMAC7.html)
SI (1) SI2857404T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201700539T1 (cg-RX-API-DMAC7.html)
TW (1) TWI585088B (cg-RX-API-DMAC7.html)
WO (1) WO2013183578A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408843B (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102224153B (zh) 2008-09-22 2014-04-30 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
LT3106463T (lt) 2008-10-22 2018-06-25 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-]pirimidino junginiai kaip trk kinazės slopikliai
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PT3205654T (pt) 2010-05-20 2019-04-22 Array Biopharma Inc Compostos macrocíclicos como inibidores de cinases trk
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
CN106132967B (zh) * 2014-03-27 2019-05-28 詹森药业有限公司 作为ros1抑制剂的化合物
AU2015238296B2 (en) * 2014-03-27 2018-10-18 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors
CA2946416C (en) * 2014-04-25 2022-07-19 Exelixis, Inc. Method of treating lung adenocarcinoma
AU2015346046B2 (en) 2014-11-16 2020-06-25 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA41667A1 (fr) 2015-06-01 2018-08-31 Loxo Oncology Inc Procede de diagnostic et de traitement du cancer
BR112017027339A2 (pt) 2015-06-18 2018-09-04 Cephalon, Inc. derivados de piperidina 1,4-substituída
CA3014432C (en) 2015-06-18 2024-05-07 Cephalon, Inc. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
CN106854174A (zh) * 2015-12-08 2017-06-16 湖南华腾制药有限公司 一种4位取代哌啶衍生物的制备方法
EP3439663B1 (en) 2016-04-04 2024-07-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2018000335A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
SI3800189T1 (sl) 2016-05-18 2023-11-30 Loxo Oncology, Inc. Priprava (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo (1,5-a)pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN107400082A (zh) * 2016-05-19 2017-11-28 湖南华腾制药有限公司 一种取代哌啶衍生物的制备方法
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
CA3055504A1 (en) * 2017-03-14 2018-09-20 Daiichi Sankyo Company, Limited Method for producing 3,6-disubstituted imidazo[1,2-b]pyridazine derivative
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3080157A1 (en) 2017-10-26 2019-05-02 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
CN109748902B (zh) * 2017-11-02 2020-11-06 杭州科巢生物科技有限公司 一种盐酸安罗替尼的制备方法
KR102078775B1 (ko) * 2017-11-29 2020-02-19 서울대학교산학협력단 항-ros1 항체 및 그의 용도
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
US12037345B2 (en) 2018-07-24 2024-07-16 Taiho Pharmaceutical Co., Ltd. Heterobicyclic compounds for inhibiting the activity of SHP2
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド FGFRチロシンキナーゼの阻害剤としての置換ピラゾロ[1,5-a]ピリジン化合物
WO2020179859A1 (ja) * 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CA3142088C (en) * 2019-05-08 2023-02-28 Tyk Medicines, Inc. Compound used as kinase inhibitor and application thereof
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202200589A (zh) * 2020-05-28 2022-01-01 瑞士商諾華公司 Mll1抑制劑及抗癌劑
CN114957259A (zh) * 2021-02-25 2022-08-30 南京明德新药研发有限公司 氰基取代的芳香双环类化合物及其应用
CA3223035A1 (en) * 2021-07-01 2023-01-05 Anheart Therapeutics (Hangzhou) Co., Ltd. Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof
WO2023220967A1 (en) * 2022-05-18 2023-11-23 Anheart Therapeutics (Hangzhou) Co., Ltd. Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds
CN114989176B (zh) * 2022-07-08 2024-08-27 深圳市新樾生物科技有限公司 咪唑并哒嗪类衍生物及其应用
CN115197115B (zh) * 2022-08-25 2024-11-08 成都金博汇康医药科技有限公司 一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用
AU2023339247A1 (en) 2022-09-07 2025-03-27 Suzhou Langrui Biopharmaceutical Co., Ltd. Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof
CN117659020A (zh) * 2022-09-07 2024-03-08 苏州朗睿生物医药有限公司 一种咪唑并[1,2-b]哒嗪衍生物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
EP1339680A1 (en) 2000-09-01 2003-09-03 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP1742921A2 (en) 2004-04-21 2007-01-17 AstraZeneca AB Pyrazole derivatives useful for the treatment of cancer
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
HUE025671T2 (en) 2005-02-04 2016-04-28 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
PL1853602T3 (pl) 2005-02-16 2010-11-30 Astrazeneca Ab Związki chemiczne
US8129403B2 (en) 2005-02-16 2012-03-06 Astrazeneca Ab Chemical compounds
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Lck阻害剤としての縮合複素環
US7776878B2 (en) * 2005-08-01 2010-08-17 Hoffmann-La Roche Inc. Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
DE102006029447A1 (de) 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
MX2009004700A (es) * 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
WO2008072682A1 (ja) 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
JP2009227599A (ja) * 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
ES2548135T3 (es) 2008-05-13 2015-10-14 Novartis Ag Heterociclos condensados que contienen nitrógeno y composiciones de los mismos como inhibidores de quinasa
CN102224153B (zh) * 2008-09-22 2014-04-30 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
KR101147550B1 (ko) * 2009-10-22 2012-05-17 한국과학기술연구원 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노[3,2-d]피리미딘 화합물
WO2012005299A1 (ja) 2010-07-07 2012-01-12 日本新薬株式会社 Rosチロシンキナーゼ阻害剤
WO2012125667A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Also Published As

Publication number Publication date
IL236075A (en) 2017-10-31
PH12014502721B1 (en) 2015-02-02
MY170326A (en) 2019-07-17
BR112014029851B1 (pt) 2023-01-03
LT2857404T (lt) 2017-11-10
AU2013272701B2 (en) 2017-12-21
TWI585088B (zh) 2017-06-01
BR112014029851A2 (pt) 2017-06-27
SI2857404T1 (sl) 2017-11-30
CA2874819C (en) 2017-06-20
MX2014014803A (es) 2015-02-12
NO2857404T3 (cg-RX-API-DMAC7.html) 2018-01-20
EP2857404B1 (en) 2017-08-23
PL2857404T3 (pl) 2018-04-30
WO2013183578A1 (ja) 2013-12-12
MX357021B (es) 2018-06-25
HUE037221T2 (hu) 2018-08-28
DK2857404T3 (en) 2017-12-04
TW201400486A (zh) 2014-01-01
US20150051190A1 (en) 2015-02-19
PH12014502721A1 (en) 2015-02-02
ZA201408843B (en) 2016-01-27
ES2648228T3 (es) 2017-12-29
EP2857404A4 (en) 2016-01-20
US9751887B2 (en) 2017-09-05
CN104520300B (zh) 2016-12-21
JPWO2013183578A1 (ja) 2016-01-28
EP2857404A1 (en) 2015-04-08
IL236075A0 (en) 2015-02-01
KR101781255B1 (ko) 2017-09-22
CN104520300A (zh) 2015-04-15
RU2014153627A (ru) 2016-08-10
AU2013272701A1 (en) 2015-01-15
IN2014MN02497A (cg-RX-API-DMAC7.html) 2015-07-17
AU2013272701A2 (en) 2015-01-22
SG11201408052WA (en) 2015-01-29
PT2857404T (pt) 2017-11-23
CO7160119A2 (es) 2015-01-15
RS56625B1 (sr) 2018-03-30
KR20150014942A (ko) 2015-02-09
HRP20171724T1 (hr) 2018-01-12
RU2635917C2 (ru) 2017-11-17
NZ702574A (en) 2016-07-29
CY1119607T1 (el) 2018-04-04
JP5814467B2 (ja) 2015-11-17
CA2874819A1 (en) 2013-12-12
US9187489B2 (en) 2015-11-17
US20160046639A1 (en) 2016-02-18
HK1207374A1 (en) 2016-01-29

Similar Documents

Publication Publication Date Title
SMT201700539T1 (it) DERIVATI IMIDAZO[1,2-b]PIRIDAZINICI COME INIBITORI DI CHINASI
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
IL235819A0 (en) Preparation of pyrrolo[b–3,2]pyridines
SG11201404969YA (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
AP2013007159A0 (en) Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
PL2812337T3 (pl) Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikk
IL227526A0 (en) Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
SG11201503977PA (en) Azaindole derivatives as jak3 inhibitors
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
PL2694513T3 (pl) Pochodne pirazolopirymidynowe
SG11201408816QA (en) 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
SG10201408059QA (en) 5-oxo-5, 8-dihydropyrido [2, 3-d] pyrimidine derivatives as camkii kinase inhibitors for treating cardiovascular diseases
SG11201500883YA (en) 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
AP3582A (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
HK1176060A (en) Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors